HilleVax Q2 2024 Earnings Report

Reported financial results for the second quarter ended June 30, 2024 and highlighted recent progress.

Key Takeaways

HilleVax reported a net loss of $40.7 million for the second quarter of 2024. The company had $245.0 million in cash, cash equivalents, and marketable securities as of June 30, 2024. They discontinued further development of HIL-214 in infants and announced a workforce reduction of approximately 40%.

NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, leading to discontinuation of HIL-214 development in infants.

Announced a workforce reduction of approximately 40% to reduce operating expenses.

Exploring potential continued development of HIL-214 and HIL-216 norovirus vaccine candidates in adults.

Cash, cash equivalents and marketable securities totaled $245.0 million as of June 30, 2024.

Previous year: -$0.74

+12.2%

Gross Profit

$0